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Abstract (250 words) 
Conversion of astrocytes to neurons, via de-differentiation to neural stem cells (NSC), may be a 
new approach to treat neurodegenerative diseases and brain injuries. The signaling factors 
affecting such a cell conversion are poorly understood, and they are hard to identify in complex 
disease models or conventional cell cultures. To address this question, we developed a serum-free, 
strictly controlled culture system of pure and homogeneous ‘astrocytes generated form murine 
embryonic stem cells (ESC)’. These stem cell derived astrocytes (mAGES), as well as standard 
primary astrocytes resumed proliferation upon addition of FGF. The signaling of FGF receptor 
tyrosine kinase converted GFAP-positive mAGES to nestin-positive NSC. ERK phosphorylation 
was necessary, but not sufficient, for cell cycle re-entry, as EGF triggered no de-differentiation. 
The NSC obtained by de-differentiation of mAGES were similar to those obtained directly by 
differentiation of ESC, as evidenced by standard phenotyping, and also by transcriptome 
mapping, metabolic profiling, and by differentiation to neurons or astrocytes. The de-
differentiation was negatively affected by inflammatory mediators, and in particular, interferon 
gamma (IFNγ) strongly impaired the formation of NSC from mAGES by a pathway involving 
phosphorylation of STAT1, but not the generation of nitric oxide. Thus, two antagonistic 
signaling pathways were identified here that affect fate conversion of astrocytes independent of 
genetic manipulation. The complex interplay of the respective signaling molecules that 
promote/inhibit astrocyte de-differentiation may explain why astrocytes do not readily form 
neural stem cells in most diseases. Increased knowledge of such factors may provide therapeutic 
opportunities to favor such conversions. 
 
Kleiderman et al.: astrocyte reactivation by FGF2 
 
4 (of 40) 
Introduction  
Astrocytes are well-recognized for their inflammatory activation upon injury, but less is 
known on factors that affect their plasticity and lineage commitment. For example, 
neurogenesis from astrocytic neural stem cells has been demonstrated in certain niches of the 
adult mammalian brain [1-4]. Outside these niches, conversion of mature astrocytes into 
functional neurons requires expression of ectopic neurogenic transcription factors [5-13]. For 
therapeutic purposes, conversion of astrocytes to neurons without genetic reprogramming 
would be favorable. 
During inflammation or disease, astrocyte activation is promoted by cytokines released from 
e.g., microglia [14-18], infiltrating leukocytes [19], or stressed neurons (ATP; reactive oxygen 
species) [20, 21]. The resultant ‘astrogliosis’ may have both detrimental and beneficial effects 
on neuron regeneration [22, 23]. Important features of severe astrogliosis are the re-entry of 
mature, non-proliferating astrocytes into the cell cycle, and the formation of glial scars [23-
27]. For instance, activation of the transcription factor NF-kB by TNF has been shown to be 
associated with a de-differentiation of astrocytes [28, 29]. Some of these astrocytes re-express 
markers normally found in neural stem cells, such as nestin [20, 30, 31]. The potential of 
astrocytes to be transformed into cells capable of generating neurons may be used for future 
neuroregenerative therapies, if more becomes known on why they normally stay within their 
astrocytic lineage in vivo [24, 32, 33]. 
Mature astrocytes do not normally proliferate in the intact brain [23, 34], but several 
molecules that induce cell cycle re-entry and reversion to stem cells have been described [35]. 
These comprise nucleotides [36, 37], and growth factors such as EGF [38, 39], FGF2 [40-42], 
or sonic hedgehog (SHH) [43]. Pioneering work by Magdalena Götz and colleagues found 
that SHH also de-differentiated astrocytes in certain mouse injury models. Astrocytes exposed 
to this factor and isolated even from uninjured brains could be converted into self-renewing 
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and neurogenic neural stem cells in vitro, although neurogenesis could not be demonstrated in 
vivo [44].  
The reason for the failure of astrocytes to form neurons in vivo might be the release of 
inhibitory factors during inflammation or disease [45]. Such signals could either prevent de-
differentiation and cell cycle re-entry [46], or they may favor astrocyte lineage commitment 
over neurogenesis (e.g., bone morphogenetic proteins (BMPs) [47, 48] ,or notch signaling 
[49]). Several factors that promote [28] and inhibit de-differentiation and neurogenic 
conversion may be released simultaneously in disease models [44, 45], and this makes it hard 
to identify targets that would allow pharmacological triggering of endogenous de-
differentiation and neurogenesis from astrocytes [10, 50]. 
An alternative approach to in vivo disease models are well-controlled cell cultures. We have 
recently established an in vitro system of pure and post-mitotic ‘murine astrocytes generated 
from embryonic stem cells’ (mAGES) [51]. These cells show transriptomic, metabolic, and 
functional (glutamate uptake, glutamine release, response to cytokines) properties similar to 
primary astrocytes. As they can be maintained in medium without serum, their inflammatory 
activations state is very low, and the culture system allows the addition or removal of single 
factors under strictly controlled conditions. We tested several factors for their capacity to de-
differentiate mAGES to NSC and found that the addition of FGF2 induced cell cycle re-entry 
and a full conversion of astrocytes into neurogenic NSC. This system was used to explore 
underlying signaling pathways. Moreover, we used the system to identify inflammatory 
factors that inhibit neurogenic conversion of astrocytes. IFN-gamma and the JAK-STAT 
pathway triggered by this cytokine were identified as important counter-regulators of de-
differentiation. 
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Materials and Methods  
Full details are given in Supporting Information. 
 
Differentiation/preparation of neural stem cells, mAGES, and primary astrocytes  
NSC and mAGES were differentiated from murine embryonic stem cells (mESC) and 
maintained as described earlier [51]. In brief, NSC were maintained in N2B27-medium [1:1 
DMEM/F12 and Neurobasal-medium, N2-supplement, B27-supplement, 2 mM Glutamax, 
100 µM β-mercaptoethanol, 7.5 µg/ml insulin, 50 µg/ml BSA] supplemented with 20 ng/ml 
EGF and FGF2. NSC were re-plated in N2B27-medium supplemented with 20 ng/ml bone 
morphogenetic protein 4 (BMP4) and differentiated into mAGES for 5 days. If mAGES were 
cultured for longer periods, medium containing 10 ng/ml BMP4 was changed every other day. 
Preparation of primary astrocytes [14, 17] is described in Supporting Information. 
De-differentiation of mAGES to NSC2 
Five days-old mAGES were washed twice with PBS, and N2B27-medium supplemented with 
20 ng/ml FGF2 was added. Medium was changed every other day. Experiments were 
performed on day 1-10. As control, cells were cultured in N2B27-medium without BMP4 and 
FGF2. To further maintain mAGES-derived NSC2, cells were re-plated at a density of 10,000 
cells per cm2 in N2B27-medium supplemented with 20 ng/ml FGF2 (± EGF) on gelatin-
coated dishes. Medium was changed every other day, and cells were passaged twice a week 
equal to original NSC. 
Differentiation of NSC/NSC2 into neurons 
NSC2 were seeded at a density of 30,000 cells per cm2 in N2B27-medium supplemented with 
10 ng/ml FGF2 on poly-L-ornithine-hydrobromide/laminin coated plates. On day 2, FGF2 
concentration was reduced to 5 ng/ml. On day 4, N2B27-medium without FGF2 was added. 
Medium was changed every other day. Experiments were performed on day 14-21. 
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Quantitative RT-PCR (qPCR), immunocytochemistry, and EdU labeling  
Quantitative PCR and immunocytochemistry have been performed as described before [51]. 
Primers and antibodies are listed in Supporting Information. To detect DNA synthesis, cells 
were incubated for 48 h with 10 µM of the thymidine analogue 5-Ethynyl-2´-deoxyuridine 
(EdU) (Baseclick, BCK-EdU555), then fixed, permeabilized, and stained according to the 
manufacturer’s instruction. Antigen-positive cells (1000 cells/condition) were counted by the 
automated screening microscope CellInsight™ CX5 (Thermo Scientific) using the pre-
defined algorithm ‘target activation’. 
Measurement of viability/proliferation 
Resazurin reduction and release of lactate dehydrogenase (LDH) were measured according to 
standard protocols [52].  
Live imaging and single cell tracking 
Dedifferentiation of mAGES was followed by time-lapse video microscopy on a Zeiss cell 
observer at 37°C. Phase contrast images were taken every 15 minutes from day 3-10 using a 
20x phase contrast objective and an AxioCamHRm camera. In addition, mAGES were 
transfected for single cell tracking with a retroviral vector encoding DsRed, as described 
earlier [53]. Pictures of the red channel were taken every 0.5 h with a 10x objective. Single 
cell tracking and the generation of consecutive lineage trees was performed using Timm’s 
Tracking Tool as described earlier [54, 55]. 
CFSE labeling and measurement of label dilution in adherent culture 
Adherent cultures of mAGES were incubated with 10 µM CFSE (in PBS) for 15 min, and 
washed thereafter. De-differentiation was initiated by addition of 20ng/ml FGF2. At the end 
of the incubation, cells were stained with H-33342, and total CFSE intensity per cell was 
measured in live cells by an automated screening microscope (CellInsight™ CX5, Thermo 
Scientific). As control, CFSE-labeled astrocytes were maintained in medium without growth 
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factors. To define the classes of non-dividing and dividing cells, a threshold has been set, 
which comprises 95% of the cells in control cultures. To normalize the data with regard to the 
starting population (day 0), cells were grouped into cells that have divided once, twice, or 
three times. Label-dilution factors per cell were used to back-calculate numbers of divisions, 
assuming a serial log2 intensity reduction per cell division. 
Statistical analysis 
Experimental data are based on three ‘biological replicates’ (different cell 
lots/differentiations); each of these data points being the means of several ‘technical 
replicates’ (repeated measures/wells within one experiment), unless otherwise stated. Data are 
presented as means ± SEM. Statistical analysis was performed using ANOVA with GraphPad 
Prism, followed by Dunnett’s post-hoc test, unless otherwise indicated. 
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Results  
Cell cycle re-entry of mature astrocytes under defined conditions 
To investigate cell cycle re-entry of murine astrocytes, cells were exposed to the growth 
factors EGF and FGF2, and incorporation of the thymidine analogue EdU was measured to 
detect DNA synthesis/proliferation. Standard primary astrocytes [14, 17], normally 
maintained in medium containing 10% serum, were cultured in N2B27-medium without 
serum to exclude effects of other growth factors. In such cultures, some basic proliferation 
was observed, and this was increased by exposure to EGF for 8 days (about 10% of cells). 
FGF2 induced proliferation of a significantly larger fraction of cells (Fig. 1A,B), and EGF 
attenuated the response to FGF2. Affected astrocytes under these conditions divided once or 
twice within 10 days, and then exited the cell cycle again. Observations beyond that time 
frame were not pursued, due to the difficulty to maintain our primary cultures without serum 
and endothelium-derived factors [56] for more than two weeks (data not shown).  
As second experimental system, homogeneous cultures of ‘murine astrocytes generated from 
embryonic stem cells’ (mAGES) [51] were used. In such cells, no basic proliferation was 
observed at all, and added EGF had no effect. However, most of the cells started to proliferate 
when exposed to FGF2 (Fig. 1C,D), and EGF did not blunt this effect. Cell cycle re-entry was 
sustainable, as mAGES exposed to FGF2 for 8 days could be re-plated and further expanded 
in N2B27-medium containing FGF2 (Supporting_Information_Fig. 1). Thus, mAGES as well 
as primary astrocytes re-enter the cell cycle in response to FGF2, although the time course 
and re-entry efficiency differed between both cell types. 
Conversion of mAGES to neural stem cells by FGF2 
Phenotypic changes associated with cell cycle re-entry were investigated by 
immunocytochemistry. Standard primary astrocyte cultures, as also observed by others [57-
59], always contained some nestin-positive cells (neural stem cell marker), and some glial 
fibrillary acidic protein (GFAP, astrocyte marker)-nestin double-positive immature astrocytes. 
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Upon FGF2 exposure, nestin-staining increased, while GFAP expression decreased. This 
switch from a genuine astrocytic phenotype to a more immature precursor cell type was also 
observed in mAGES (Fig. 1B,D; Supporting_Information_Fig. 2A,B). In the latter cultures, 
star-shaped astrocytes with fine radial processes adopted hypertrophic processes (typically 
seen in reactive astrocytes) within the first few days of FGF2 exposure. At day 6, they 
adopted a bipolar morphology with two elongated processes, and finally the typical 
morphology of neural stem cells (NSC) was observed (Supporting_Information_Fig. 3). Thus, 
astrocytes exposed to FGF2 did not only re-enter the cell cycle, but also generated neural 
stem-like cells (NSC2), which could be maintained (by FGF2 or by FGF2 plus EGF) in a self-
renewing state for ≥14 passages (Fig. 1E, Supporting_Information_Fig. 1).  
A quantification of this conversion showed that EdU incorporation and downregulation of 
GFAP started from day 5-6. Upregulation of nestin expression started directly after FGF2 
exposure, and increased continuously (Fig. 2A,B).  
The mAGES cultures were selected for further studies on cell cycle re-entry as they are more 
homogeneous, show no basic proliferation and no need for serum. To ascertain that all cells in 
these cultures were fully differentiated astrocytes, mAGES were cultured for one month in 
BMP4-containing medium, i.e., under conditions in which transiently-silenced precursor cells 
are unlikely to survive [60]. The subsequent withdrawal of BMP4 and exposure to FGF2 
resulted in a conversion into NSC2 with the same time course and efficiency as with 5-days 
old mAGES (Fig. 2C). Removal of BMP4 did not induce a de-differentiation within 8 d as 
shown by a lack of EdU incorporation. Moreover, we repeated the process with mAGES 
derived from three single cell clones of NSC, and with iPS-derived mAGES. In all cultures 
nestin and EdU incorporation were upregulated by FGF2, while GFAP-expression was 
downregulated (Fig. 2D). Thus, conversion of mAGES to NSC2 required FGF2 and was 
generalizable for various NSC. 
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Need for FGF2 signaling, but not EGF, for mAGES de-differentiation  
For investigation of the signaling events involved in the conversion of mAGES into NSC2, 
phosphorylation of key proteins was quantified in the absence or presence of pathway-specific 
kinase inhibitors (Fig. 3A). An increased phosphorylation of ERK (pERK) and AKT (pAKT) 
was observed in response to FGF2 (Fig. 3B); levels of phosphorylated p38, JNK, or c-jun did 
not change (Supporting_Information_Fig. 4A). SU5402 (inhibitor of the FGF receptor 
(FGFR1) tyrosine kinase) inhibited the FGF2-induced phosphorylation of ERK and AKT 
(Fig. 3B,C) at non-cytotoxic concentrations (Supporting_Information_Fig. 4B). This was 
paralleled by an inhibition of the de-differentiation of mAGES in the presence of FGF2, as 
seen from reduced proliferation, inhibited EdU incorporation, and reduced expression of 
nestin (Fig. 3D,E). Thus, FGF receptor kinase activity was necessary for the conversion of 
mAGES to NSC2. 
While Ly294002 (inhibitor of AKT phosphorylation) did not affect the response of mAGES 
exposed to FGF2 (data not shown), the MEK1/2 inhibitor U0126 (prevention of pERK 
formation) (Supporting_Information_Fig. 5A) inhibited the FGF2-induced proliferation of 
mAGES (Supporting_Information_Fig. 5B). U0126 also inhibited DNA synthesis in mAGES 
exposed to FGF2 (Supporting_Information_Fig. 5C) at non-cytotoxic concentrations 
(Supporting_Information_Fig. 5D), while FGF2-induced upregulation of nestin was not 
affected (Supporting_Information_Fig. 5C). This suggests that FGF receptor-induced 
phosphorylation of ERK, but not AKT, drives cell cycle re-entry, but not necessarily 
acquisition of other stem cell properties (nestin regulation). 
Since other studies described rather an involvement of EGF than FGF2 in the de-
differentiation of astrocytes, we investigated a putative role of endogenously produced EGF 
[38, 39]. The EGF receptor kinase inhibitor gefitinib inhibited EGF-induced phosphorylation 
of ERK and AKT at non-cytotoxic concentration of 0.1 µM (Fig. 3F, 
Supporting_Information_Fig. 6A), while phosphorylation of ERK and AKT induced by FGF2 
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was not affected (Fig. 3F, Supporting_Information_Fig. 6D). To test if any indirect EGF 
receptor activation is necessary for the de-differentiation of mAGES, cells were co-exposed to 
FGF2 plus gefitinib (1 µM). The EGF receptor inhibitor had no effect on EdU incorporation, 
nestin expression (Fig. 3G), or proliferation (Supporting_Information_Fig. 6B,C). Thus, EGF 
is neither sufficient (Fig. 1C) nor necessary for the conversion of mAGES into NSC2. 
Characterization of NSC2 as multipotent neural stem cells 
After having found that NSC2 are able to self-renew (> 14 passages), we investigated their 
developmental potency with respect to neurogenesis and gliogenesis: when NSC2 were 
exposed to BMP4, they adopted the typical star-shaped morphology of astrocytes within 3 
days, and expressed GFAP and aquaporin 4 (Aqp4) to a similar extent as mAGES (Fig. 
4A,B). The resultant astrocyte population was therefore termed ‘mAGES2’. To investigate the 
neurogenic potential of NSC2, they were re-plated on poly-ornithine/laminin, and FGF2 was 
gradually withdrawn from the medium to allow spontaneous differentiation. After 14 days, 
the culture consisted of 60% βIII-tubulin-positive (TUJ1) neurons, and about 30% GFAP-
positive astrocytes (Fig. 4C,D). Nestin expression was found to decrease to 20% after an 
additional week's culture (not shown). Conversely, most TUJ1-positive cells expressed the 
post-mitotic neuronal marker NeuN in the nucleus (Fig. 4E). In summary, NSC2 were found 
to be multipotent stem cells, giving rise to astrocytes and neurons with the same 
differentiation efficiency as the original NSC population.  
Comparison of NSC2 with NSC concerning gene expression and function 
To further characterize the phenotype of NSC2, several cell type marker genes were selected, 
and their expression levels were compared with those found in mAGES and NSC (Fig. 5A). 
All astrocyte markers were lower in NSC/NSC2 than in mAGES. The glutamate transporter 
Glt-1 (SLC1A2) and the calcium-binding protein S100B were even lower expressed in NSC2 
than in NSC. Neural stem cell markers (Nestin, Blbp, Olig2) were upregulated in NSC2 (and 
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NSC) compared with mAGES. Thus, qPCR analysis confirmed the similarity of NSC2 with 
NSC. 
Next, expression of over 34,000 genes (covered by 45,000 probesets) was measured in mESC, 
NSC, mAGES, and NSC2 by microarray hybridization. Principal component analysis of 
global gene expression showed clustering of NSC2 and NSC samples as opposed to distinct 
groupings for the mESC and mAGES samples, and thus demonstrated the close similarity of 
NSC2 and NSC (Fig. 5B). This was further confirmed by analysis of significantly 
differentially expressed genes (DEG): no DEG was found for the NSC/NSC2 comparison. 
For a targeted comparison, genes identified previously to distinguish astrocytes from neural 
stem cells [51] were selected. A heatmap of their normalized expression values, extracted 
from the microarray data, confirmed the similarity of NSC2 and NSC, and their pronounced 
differences to mAGES (Fig. 5C).  
The high proportion of astrocyte genes in the above comparisons may obscure minor 
differences between the NSC populations. Therefore, we used a recently-identified set of in 
vivo NSC-specific genes [32] to compare NSC2 with NSC and mAGES. More than 70% of 
these marker genes showed higher expression in NSC2/NSC than in mAGES 
(Supporting_Information_Fig. 8), demonstrating conformity of NSC2 and NSC. The 
remaining 30% showed high variability in mAGES samples, and were here not suitable to 
clearly distinguish NSC from mAGES. 
After this detailed phenotyping, functional comparisons were performed on the basis of 
features already known to differ between NSC and mAGES [51]. First, inflammation-related 
signaling was explored. Cells were exposed to an inflammatory cytokine mix (TNFα, IL1β, 
and IFNγ) for 30 min, and NFkB translocation was measured. NSC2/NSC showed no 
response at all, while more than 90% of the cells in mAGES/mAGES2 cultures showed NFkB 
translocation into the nucleus (Fig. 5D). Thus, NSC2 are clearly not reactive astrocytes. A 
comparison of the metabolism showed that mAGES2/mAGES released citrate, and exhibited 
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similar glucose consumption and lactate release rates (Fig. 5E,F). In contrast, NSC/NSC2 did 
not release citrate and showed higher metabolic rates compared with mAGES/mAGES2. 
These data confirm a complete conversion from an astrocytic to a neural stem cell identity, 
when mAGES are de-differentiated to NSC2. 
Evidence for direct NSC2 generation from differentiated astrocytes  
Although the mAGES population comprises >99% astrocytes (GFAP-positive) [51], it cannot 
be entirely excluded that NSC2 arise from a minor subpopulation of non-differentiated cells 
that is re-activated by FGF2. Therefore, two competing hypotheses may explain the 
generation of NSC2 (Fig. 6A): the first assumes that some cells within the mAGES 
population did not differentiate into mature astrocytes upon exposure to BMP4, but rather 
stayed in a dormant stem cell state. They may start to proliferate upon exposure to FGF2, and 
overgrow the mAGES. The second hypothesis assumes that a large proportion of mAGES re-
enters the cell cycle, and convert into NSC.  
For hypothesis-1 to be true, the original mAGES would need to die upon exposure to FGF2, 
in order to make space for the expanding NSC, and to explain the observed loss of GFAP-
positive cells. Therefore, we carefully examined signs of cell death, and we also measured 
release of LDH into the medium as integral measure of putatively ongoing cell death. No 
indication of cell death was observed (Supporting_Information_Fig. 10A). Hypothesis-1 
would be strengthened, if quiescent stem cells could be identified. However, we did not 
identify any CD133+ cells, and the mAGES cultures were homogeneously Ki67-, p27+, within 
the range of our detection limits [51]. 
Hypothesis-2 would be supported, if intermediate cell stages would be identified that combine 
properties of astrocytes and proliferating cells; i.e., GFAP- and/or aquaporin 4 (Aqp4) -
positive astrocytes should be observed to re-enter the cell cycle and incorporate EdU into 
DNA upon exposure to FGF2. For this purpose, cells double positive for EdU and an 
astrocyte marker were identified at different time points during the 8-day de-differentiation 
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process (Fig. 6B). At all timepoints, most of the proliferating (EdU-positive) cells co-
expressed GFAP and/or Aqp4 (Fig. 6C,D). After day 7, the proportion of GFAP and EdU 
double-positive cells decreased, consistent with the downregulation of GFAP after prolonged 
FGF2 exposure. These data indicate that mature, GFAP- and Aqp4-positive astrocytes re-
entered the cell cycle in response to FGF2. 
Three imaging approaches were used to gain further insight: first, we used an established 
method of fluorescent label (CFSE) dilution [61] (adapted to adherent culture) to calculate the 
percentage of dividing cells. A histogram of total CFSE intensity in 20,000 cells showed that 
label intensity decreased in 72% of the cells in FGF2-exposed cultures (to indicate at least one 
division), compared to control cells not exposed to FGF2. Taking into account the 
quantification of label dilution steps (2x, 4x, 8x) in cells, and calculating back the respectively 
increased cell numbers at the time point of analysis, we found that >50% of the mAGES 
originally present at day 0 had divided at least once (Fig. 6E, Supporting_Information_Fig. 
10B).  
Second, to confirm the CFSE-labeling data, and to directly follow mAGES division, live cell 
time lapse imaging was performed. The mAGES were transfected with DsRed to track single 
cells (using Timm’s Tracking Tool, which has been developed to track freshly isolated neural 
stem cells in vitro [54, 55]) (Supporting_Information_Fig. 11B,D, 
Supporting_Information_Video 1). Lineage trees were produced for 84 cells, of which 42 
(50%) divided during 10 days of FGF2 exposure. Many of the cells divided once (19%), while 
another large subpopulation (19%) divided ≥3 times (Supporting_Information_Fig. 10C). 
Most of the cells (60%) started their first cell division on days 6-8 of FGF2 exposure 
(Supporting_Information_Fig. 10D), which is consistent with EdU incorporation starting to 
increase at day 5.  
As third imaging approach, we followed the cells by phase contrast time-lapse microscopy in 
low density cultures, to make sure that the entire population could be captured. This 
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independent set of experiments also showed that around 50% of the mAGES (flat cells with a 
star-shaped morphology) divided (Supporting_Information_Fig. 11A,C, 
Supporting_Information_Video 2). After two to three divisions, cells changed their 
appearance and adopted a morphology similar to that of NSC (video 2, 
Supporting_Information_Fig. 3). No cell division was observed in control cultures maintained 
in medium containing no factors (Supporting_Information_Video 3). Thus, a large body of 
evidence supports hypothesis-2. 
Blocking the generation of NSC2 from mAGES by IFNγ signaling 
To investigate how de-differentiation of astrocytes may be affected by mediators present in a 
pathological environment, mAGES were exposed to inflammatory cytokines (TNFα, IL1β, 
IFNγ) during de-differentiation with FGF2. For a first overview, resazurin reduction was 
measured to assess cell proliferation in response to FGF2. TNFα or IL1β alone did not reduce 
proliferation, but a combination of both cytokines was effective. IFNγ, alone or in 
combination with other cytokines, also attenuated the proliferation of mAGES (Fig. 7A). 
These data were confirmed, when EdU incorporation was measured: the complete cytokine 
mix (CCM) or various combinations of the three cytokines reduced DNA synthesis to a large 
extent (Fig. 7B). IFNα or IFNβ did not show any effect on the FGF2-induced de-
differentiation of mAGES (not shown). Thus, the IFNγ receptor specifically affected astrocyte 
de-differentiation, in addition to its effect described directly on quiescent NSC [62]. Notably, 
the downregulation of GFAP and the upregulation of nestin during de-differentiation were 
affected by the same cytokine combinations as for proliferation/DNA synthesis, but the 
overall effect size was smaller (Supporting_Information_Fig. 12). 
As IFNγ alone was sufficient to inhibit the de-differentiation of mAGES, its mechanism of 
action was further explored. Ruxolitinib (Rux), an inhibitor of JAK1/2 (Fig. 3A), was used to 
test the role of the JAK/STAT pathway. In mAGES exposed to FGF2 plus IFNγ or CCM, co-
treatment with ruxolitinib prevented the attenuation of proliferation, and of EdU 
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incorporation, which is otherwise triggered by IFNγ or CCM (Fig. 7C,D, 
Supporting_Information_Fig. 13A,B). Western blot analysis revealed that the same 
concentration of Rux, which showed strong effects on cell fate (1 µM), also completely 
blocked phosphorylation of STAT1 after short-term exposure to IFNγ or CCM (Fig. 7E,F), or 
after prolonged exposure (Supporting_Information_Fig. 13C). We also found that neither 
IFNγ nor ruxolitinib affected upstream FGF2 signaling (phosphorylation of ERK) 
(Supporting_Information_Fig. 13D). From this, we conclude that the JAK/STAT pathway, 
triggered by IFNγ, attenuates astrocyte de-differentiation downstream of FGF2 receptor 
surface expression and proximal signaling (Fig. 3A). 
Kleiderman et al.: astrocyte reactivation by FGF2 
 
18 (of 40) 
Discussion  
It is widely accepted that post-mitotic astrocytes may re-enter the cell cycle under certain 
conditions [20, 44]. However, de-differentiation of genuine astrocytes into neural stem cells 
and their conversion into neurons usually requires genetic reprogramming or pathological 
situations, like trauma, excitotoxicity, or stroke [50, 62-69]. It has been suggested that 
migration of cells from the stem cell niches to the lesion site also contributes [70] to the in 
vivo emergence of neurogenic cells (identified by in vitro neurosphere assays [44, 67]). Most 
likely, various mechanisms contribute to the astrocyte activation/de-differentiation observed 
in vivo, and they are paralleled by large heterogeneity within the astrocyte population and the 
NSC [22, 62, 68, 71, 72]. We chose here a simplified experimental approach that allowed 
direct and quantitative studies of cell cycle re-entry of mature astrocytes, not manipulated by 
molecular biology approaches. The high homogeneity of the mAGES astrocyte cultures used 
here allowed quantifications of cell type, function, and plasticity over long time spans and 
with little background noise. This facilitated the identification of an FGF2 receptor pathway 
(involving tyrosine kinase activation and ERK phosphorylation) as a signal for cells to resume 
proliferation. The neurogenic neural stem-like cells (NSC2) derived from mAGES astrocytes 
upon FGF2 exposure resembled NSC concerning self-renewal, phenotype, metabolism, 
proliferation behavior, and bi-potent differentiation capacity. Thus, the type of neurogenic 
cells generated here does not resemble reactive astrocytes (that may divide once or twice in 
the brain, and retain many astrocytic markers), but rather exemplifies full reversion to an 
NSC-like state. Notably, cultures of mAGES could be converted into neurons without any re-
plating steps, and only by change of medium conditions within about three weeks (not 
shown). However, this conversion of astrocytes to neurons in a cell culture dish is not to be 
confused with trans-differentiation [73]; in our system, mAGES first de-differentiated into 
NSC2 (10 days; +FGF2), and afterwards generated neurons (14 days; -FGF2). 
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A central issue of all de-differentiation studies with primary cells or other complex cell 
cultures is the exclusion of a major role of an already present stem cell population, or of a 
transgene affecting the cell cycle [29]. Although mAGES have been carefully characterized 
and phenotyped for the absence of cells with quiescent NSC markers [51], it was important to 
provide direct evidence that a majority of astrocytes in the cultures transformed into NSC2. 
Co-staining of EdU and Aqp4 suggested that indeed mature astrocytes re-entered the cell 
cycle. CFSE-label dilution and live imaging of mAGES cultures, as a direct measure of cell 
division, further confirmed the cell cycle re-entry of about 50% of the cells (within the 
experimental time span observed). This high percentage i) excludes the proliferation of only a 
minor subpopulation within mAGES cultures as major cause of NSC2 formation, and ii) 
corroborates a high efficiency of astrocyte de-differentiation under optimal conditions. For 
comparison, 22.5% of the astrocytes isolated from murine brains after stab-wound injury were 
able to form neurospheres [44].  
In some studies, EGF has been shown to induce proliferation in astrocytes [38, 39]. This was 
not confirmed here, although mAGES expressed functional EGF receptors (Fig. 3A). Even an 
indirect contribution was excluded, as de-differentiation of mAGES was possible in the 
presence of non-cytotoxic, but effective concentrations of the EGF receptor inhibitor gefitinib. 
In view of these findings, it may be worth investigating in models that have been assumed to 
be EGF-dependent [38], whether production of endogenous FGF2 after exposure to EGF [39] 
would provide the pivotal signal for proliferation of cells. In fact, primary astrocytes have 
been observed to re-enter the cell cycle in response to FGF2 [40-42]. Discrepancies between 
studies may be due to different signaling systems being employed, depending on the maturity 
status of cells: EGF may have a more important role for less differentiated cells, and such 
cells are found as a subpopulation in primary astrocyte cultures. 
The findings of our study are consistent with the broad role of FGF2 in neurodevelopment 
[74] and acute CNS injuries [45]. The cytokine stimulates proliferation of NSC in stem cell 
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niches [45, 75-77], and it improves regeneration after traumatic injury or ischemia [78, 79]. 
The high levels of FGF2 found in acute neurotrauma correlate with a proliferation of 
astrocytes in such conditions, while low or absent regulation in chronic neurodegenerative 
diseases, such as Parkinson’s disease [80], correlate with a failure of astrocytes to proliferate 
[44]. The importance of FGF2 (in contrast to EGF) on NSC maintenance and astrocyte 
differentiation inhibition is in good agreement with earlier findings on rat [81]. However, 
terminally-differentiated astrocytes generated by exposure of rat NSC to BMP4 did not de-
differentiate upon exposure to FGF2, and thus behaved differently from mAGES. 
To obtain a pure population of fully-differentiated astrocytes, an alternative to mAGES is the 
use of primary cultures in combination with FACS sorting or panning for genuine astrocyte 
markers [56, 82]. In our hands, the required manipulations and culture conditions led to a 
slight inflammation-like activation of (untreated) astrocytes, and such conditions largely 
change their properties [22, 23, 83]. The findings presented here, confirm the pronounced 
effects that external inflammatory factors may have: for instance, the model system 
established here allowed for the identification of IFNγ as one of the pathologically-relevant 
inflammatory factors likely to attenuate the de-differentiation of astrocytes in many disease 
models. IFNγ (and complete cytokine mix) inhibited the de-differentiation of mAGES by a 
phosphorylation of STAT1, while inhibition of the JAK/STAT pathway by ruxolitinib 
restored FGF2-induced proliferation. The exact interference between STAT1 phosphorylation 
and FGF2 signaling needs further examination (Fig. 3A). The astrocyte de-differentiation was 
not only attenuated by IFNγ, a cytokine produced in vivo from infiltrating cells [19, 84] and 
from microglia [85, 86], but also by the very common combination of microglia-derived [14-
18] inflammatory factors TNF plus IL-1. In our study, IL-1 or TNF alone did not attenuate de-
differentiation. This may be due to an intrinsic property of such NF-kB-inducing cytokines to 
rather support de-differentiation of astrocytes [28, 87]. 
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In summary, we have presented here evidence for defined signaling pathways that 
antagonistically control the conversion of astrocytes to NSC, i.e. cells capable of forming new 
neurons. The experimental system developed on the basis of these findings may be used to 
identify targets, and possibly to screen for new drug candidates that foster the conversion of 
astrocytes to neurons in CNS pathologies, and that could then be tested in vivo for their 
efficacy. 
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Figure legends  
Figure 1: Cell cycle re-entry of mature astrocytes under controlled conditions.  
(A): Primary murine astrocytes were exposed to 20 ng/ml FGF2 or 20 ng/ml EGF or 
combinations thereof for 8 d. The nucleoside analogue EdU (10 µM) was added during the 
last 48 h. EdU incorporation into the DNA was visualized by immunocytochemistry, and the 
number of EdU-positive nuclei was counted by an automated screening microscope (1000 
nuclei/condition). Data are means ± SEM for three cell preparations. ***, p <0.0001; *, p 
<0.01 (Tukey’s posttest). (B): Representative images are shown for cells treated as in (A). 
Left: EdU incorporation was visualized by immunocytochemistry (green), and nuclei were 
stained with H-33342 (red). Right: glial fibrillary acidic protein (GFAP, green) and nestin 
(red) were visualized by immunocytochemistry, and nuclei were stained with H-33342 (blue). 
(C): Three different lots of murine astrocytes generated from embryonic stem cells (mAGES) 
were treated and analyzed as in (A). In control cultures (N2B27, serum-free) medium without 
additional factors), less than one cell per condition was found to be EdU-positive (< 0.1%). 
Data for cells exposed to growth factors are as indicated (given as means ± SEM). ***, p 
<0.0001; ns, not significant (Tukey’s posttest). (D): The mAGES were immunostained as in 
(B); a scale bar and color keys are displayed on the images. (E): Summary of the experimental 
procedure and findings of A-D: FGF2 drives the transformation of GFAP-positive, non-
proliferating astrocytes (here exemplified by the pure and defined population of mAGES to 
proliferating nestin-positive neural stem cells (here called NSC2). 
Figure 2. Conversion of mAGES to neural stem cells by FGF2  
(A): Cultures of mAGES were exposed to 20 ng/ml FGF2 for 1-9 days, before they were 
fixed. EdU was added 48 h prior to termination of the experiment. The percentage of EdU-
positive nuclei was determined. (B): GFAP and nestin were visualized by 
immunocytochemistry in cells treated as in (A). The percentage of positive cells is displayed. 
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(C): As shown in the schematic, neural stem cells (NSC) were differentiated for 30 days to 
mAGES by exposure to BMP4, before they were exposed to FGF2  (0 or 20 ng/ml) for 8 
days. EdU was added to the medium for the last 48 h. GFAP and nestin were visualized by 
immunocytochemistry. Nuclei were stained with H-33342. FGF2 induced a conversion of 
fully mature mAGES into neural stem-like cells (=NSC2). Note that exposure of NSC to 
BMP4 for 5 days leads to homogeneous cultures of non-proliferating mAGES; long-term 
differentiation was chosen to render unlikely the presence of remaining NSC. (D): Embryonic 
stem cell-derived NSC (pool), three single cells clones of these NSC (#1-3), and induced 
pluripotent stem cell (iPS)-derived NSC were differentiated to mAGES (the left side of the 
diagram shows a typical phenotypic outcome for pool cells). Such mAGES were exposed to 
FGF2 for 8 days, and incubated with EdU for the last 48 h. GFAP, nestin, and EdU-
incorporation were visualized by immunocytochemistry, and the percentage of positive cells 
was determined by an automated screening microscope (means ± SEM). n.d., not detectable.  
Figure 3. Need for FGF2 signaling, but not EGF, for mAGES de-differentiation.  
(A): Overview of inhibitor targets and signaling pathways affecting de-differentiation from 
mAGES to neural stem-like cells (NSC2). (B): Cultures of mAGES were pre-incubated for 30 
min with SU5402 (10 µM), and exposed to FGF2 (20 ng/ml) for 20 min. Cell lysates were 
analyzed by Western blot for AKT and ERK, and their phosphorylated forms (pAKT, pERK). 
(C): Densitometric quantification of the ratio between phosphorylated and un-phosphorylated 
proteins from three experiments as in (B). ***, p <0.0001; **, p <0.001 (versus FGF2). (D): 
To measure proliferation, mAGES were exposed for 8 days to 0 (ctrl) or 20 ng/ml FGF2 plus 
increasing concentrations of SU5402, and resazurin reduction was used as surrogate measure 
of cell number. The data indicate the percentage of increased resazurin fluorescence signal 
(proportional to cell number) relative to ctrl conditions. (E): Nestin protein and EdU 
incorporation were visualized in mAGES treated as in (D), and incubated with EdU for the 
last 48 h. Positive cells were counted by an automated screening microscope. (F): The 
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mAGES were pre-incubated for 30 min with gefitinib (Gef), and exposed to 20 ng/ml EGF or 
FGF2 for 20 min, before AKT, ERK, and their phosphorylated forms were determined by 
Western blot. (G): The mAGES were exposed for 8 days to 0 (ctrl) or 20 ng/ml FGF2 plus 
increasing concentrations of gefitinib; EdU was added for the last 48 h. EdU incorporation 
and nestin protein were visualized by immunocytochemistry. Positive cells were counted by 
an automated screening microscope. Data are means ± SEM. 
Figure 4. Characterization of NSC2 as multipotent neural stem cells  
NSC2, i.e. neural stem-like cells obtained from mAGES, were differentiated into either 
astrocytes (mAGES2) with BMP4 for 3 days (A,B) or into neurons (C, D, E). (A): Phase 
contrast images show typical neural stem cell morphology of NSC and NSC2 and astrocytic 
morphology of mAGES and mAGES2. (B): Resentative immunofluorescence images of 
mAGES2, generated from NSC2 by exposure to BMP4 (for 3 days): glial fibrillary acidic 
protein (GFAP, green), and either aquaporin 4 (Aqp4) or nestin are shown (red). Nuclei were 
stained with H-33342 (blue). (C): NSC2 were differentiated into neurons by a stepwise 
reduction and subsequent withdrawal of FGF2 for 14 days. After fixation, βIII-tubulin (TUJ1, 
red) and either GFAP or nestin (green) were visualized by immunocytochemistry. Nuclei 
were stained with H-33342 (blue). (D): Either NSC or NSC2 were differentiated into neurons 
and stained as in (C). Then, the percentage of antigen-positive cells was counted by an 
automated screening microscope in three different experiments (data are means ± SEM). (E): 
Phenotyping of neurons generated from NSC2 by co-immunostaining for βIII-tubulin (TUJ1, 
red) and NeuN (green). Black/white images show individual fluorescent channels for clarity; 
the colored composite image combines both channels. 
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Figure 5. Comparison of primary (NSC) and secondary (NSC2) neural stem cells for gene 
expression, metabolism and inflammatory competence.  
(A): Expression levels (mRNA, measured by qPCR) in NSC, NSC2, and mAGES of astrocyte 
markers (Gfap, Aqp4 (aquaporin), Glt-1 (Slc1A2, glutamate transporter), Kir4.1 (inwardly-
rectifying potassium channel), Aldh1L1, S100b), or NSC markers (nestin, Olig2, Blbp). ***, 
p <0.0001; **, p <0.001; *, p <0.01; ns, not significant (versus NSC2). (B): Transcriptome 
data (microarray) obtained for murine embryonic stem cells (mESC), NSC, mAGES, and 
NSC2. The 2D principal component analysis plot shows 4 biological replicates of each cell 
type and the 95% confidence interval as shaded ellipses. (C): Heatmap of gene expression 
values for known  astrocyte (blue) and NSC (red) marker genes (listed vertically) [51]. Z-
scores of normalized  expression data plotted for four NSC, four mAGES, and three NSC2 
samples (listed horizontally). Blue colors represent low, red colors high expression, with z-
scores ranging from 1.4 to -1.4. Full gene names and corresponding expression values are 
listed in Supporting_ Information_Fig. 7. (D): Cells were exposed to a cytokine mix (=10 
ng/ml TNFα, 10 ng/ml IL1β, 20 ng/ml IFNγ) for 30 min, and immunostained for the 
transcription factor NFκB. Cytosol/nucleus ratio of NFkB was measured by an automated 
screening microscope to identify cells with NFkB nuclear translocation. (E): Citrate was 
measured in the supernatant after 3 and 24 h to calculate citrate release (normalized to total 
protein content). (F): Glucose/lactate concentrations were measured in the supernatant after 3 
and 24 h. Uptake/release rates (normalized to total protein content) were calculated. Data are 
means ± SEM from two biological replicates. 
Figure 6. Evidence for generation of NSC2 from differentiated astrocytes.   
(A): Two working hypotheses on the origin of NSC2 have been formulated for further testing. 
Hypothesis-1: putative nestin-positive quiescent stem cells (red) within the mAGES 
population (<1%) are stimulated by FGF2 to proliferate (green nuclei), while original 
mAGES (blue) die. Hypothesis-2: FGF2 induces cell cycle re-entry of a large subpopulation 
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of mAGES (green nuclei); these convert to GFAP+/nestin+-positive cells, and later to 
nestin+/GFAP- NSC. (B): Experimental design to investigate the phenotype of transition cells: 
mAGES were exposed to FGF2 (0 (blue)/20 ng/ml (red)) for up to 7 days; EdU was added for 
the last 48 h before immunostaining. (C): Cells were treated as in (B). EdU+/GFAP+, and 
EdU+/GFAP- cells were counted by high-content imaging. (D): The experiment described in 
(C) was performed with Aquaporin 4 (Aqp4)-staining instead of GFAP. (E): The mAGES 
were exposed to FGF2 (20 ng/ml) for 10 days, and the percentage cells (from original 
population) that divided at least once during this period was scored. To identify dividing cells, 
two different methods were used. Left: mAGES were stained with carboxyfluorescein (CFSE) 
before the experiment; quantification of CFSE-fluorescence per cell after the experiment was 
used to identify cells that had divided 0, 1, 2, 3 or several times, based on label dilution. 
Right: live-cell continuous time-lapse imaging (tracking of 84 DsRed-transfected single cells 
was used (details in Supporting_Information_Fig. 10,11). All data are means ± SEM of three 
(left) or two (right) biological replicates.  
Figure 7. Block of the generation of NSC2 from mAGES by IFNγ signaling.  
(A): The mAGES were exposed to 20 ng/ml FGF2 for 8 days, and resazurin reduction was 
used as surrogate measure of cell number. Data indicate the percentage of increased resazurin 
fluorescence signal (proportional to cell number) relative to ctrl conditions (no FGF2). FGF2-
exposed cells were co-treated with various combinations of inflammatory cytokines (10 ng/ml 
TNFα, 10 ng/ml IL1β, 20 ng/ml IFNγ) or complete cytokine mix (CCM). Data are means ± 
SEM; ***, p <0.0001; *, p <0.01; ns, not significant (versus FGF2). (B): The experiment was 
performed as in (A), with EdU added during the last 48 h, and staining of nuclei with H-
33342. Percentage of EdU-positive cells was quantified. (C): The mAGES were exposed to 
20 ng/ml FGF2 for 8 days. FGF2-exposed cells were co-treated with 20 ng/ml IFNγ and 
various concentrations of ruxolitinib (Rux). EdU was quantified as in (B). (D): The 
experiment was performed as in (C), with CCM instead of IFNγ. (E): The mAGES were pre-
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incubated for 30 min with ruxolitinib (1 µM), and exposed to FGF2 (20 ng/ml) and/or IFNγ 
(20 ng/ml) for 20 min. Phospho-STAT1 (pSTAT1) was analyzed by Western blot (actin as 
loading control). The experiment was repeated once with similar result. (F): The experiment 
was performed as in (E), with CCM instead of IFNγ. The experiment was repeated once with 
similar result.  
Supplemental figure Fig. S1: Self-renewal and multipotency of NSC2 
NSC2 derived from mAGES after 10 d exposure to FGF2 were re-plated and maintained in 
N2B27-medium supplemented with 20 ng/ml FGF2 until passage 14. At passage 14, cells 
were re-plated for differentiation to astrocytes (3 d, 20 ng/ml BMP4) or neurons (14 d). 
Cultures of NSC2, mAGES2 derived from NSC2, and neurons derived from NSC2 were fixed 
and stained for phenotypic markers. Nestin, GFAP or ßIII-tubulin (TUJ1) were detected by 
immunocytochemistry. DNA was stained with H-33342. NSC2 maintained in FGF2-
containing medium for 14 passages had the same doubling time and differentiation capacity as 
fresh NSC2. 
Supplemental figure Fig. S2: Single-channel images of GFAP and nestin in mAGES exposed 
to FGF2.  
(A): Single-channel images of Fig. 1B. Primary murine astrocytes (ctrl, no factors) were 
exposed to 20 ng/ml FGF2 for 8 d. Right: glial fibrillary acidic protein (GFAP, green) and 
nestin (red) were visualized by immunocytochemistry. (B): Single-channel images of Fig. 1D. 
The mAGES (ctrl, no factors) were exposed to 20 ng/ml FGF2 for 8 d. GFAP (left) and nestin 
(right) were visualized by immunocytochemistry. (C): Single-channel images of Fig. 2C. 
NSC were differentiated to fully mature mAGES for 30 days with BMP4, before they were 
exposed to 20 ng/ml FGF2 or medium without additional factors (no factors) for 8 days. 
GFAP (left) and nestin (right) were visualized by immunocytochemistry. Note that exposure 
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of NSC to BMP4 for 5 days leads to homogeneous cultures of non-proliferating mAGES; 
long-term differentiation was chosen to render unlikely the presence of remaining NSC. 
Supplemental figure Fig. S3: Morphological changes in mAGES exposed to FGF2. 
The mAGES (ctrl, no factors) were exposed to 20 ng/ml FGF2 and cells were fixed and 
stained every 24 h for 8 days. GFAP and Nestin expression was detected by 
immunocytochemistry. DNA was stained with H-33342. 
Supplemental figure Fig. S4: Block of FGF2-induced de-differentiation of mAGES by SU5402 
and U0126.  
(A): Cultures of mAGES were pre-incubated for 30 min with the FGF receptor inhibitor 
SU5402 (10 µM), and exposed to 20 ng/ml FGF2 for 20 min. Cell lysates were analyzed by 
Western blot for p38, its phosphorylated form (p-p38), phosphorylated JNK (pJNK), and 
phosphorylated c-Jun (p-c-Jun). (B): The mAGES were exposed to increasing concentrations 
of SU5402 in medium containing 10 ng/ml BMP4 for 8 days. Resazurin reduction was 
normalized to control without SU5402 as a measure of viability. (C,D): The mAGES were 
exposed to 10 ng/ml BMP4 (C) or 20 ng/ml FGF2 (D) for 8 days plus 10 µM SU5402 or the 
ERK inhibitor U0126 (10 µM). Cells were incubated with the nucleoside analogue EdU for 
the last 48 h, and EdU incorporation and Nestin protein (red) were visualized by 
immunocytochemistry. Nuclei were stained with H-33342 (blue).  
 
Supplemental figure Fig. S5: ERK phosphorylation is required for de-differentiation of 
mAGES   
(A): Cultures of mAGES were pre-incubated for 30 min with 10 µM U0126, and exposed to 
20 ng/ml FGF2 for 20 min. Cell lysates were analyzed by Western blot for Akt and ERK, and 
their phosphorylated forms (pAkt, pERK). (B): The mAGES (ctrl, no factors) were exposed to 
20 ng/ml FGF2 plus increasing concentrations of the ERK inhibitor U0126 for 8 days. 
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Resazurin reduction was used as surrogate measure of cell number. The data indicate the 
percentage of increased resazurin fluorescence signal (proportional to cell number) relative to 
ctrl conditions. (C): The mAGES were treated as in (A), and incubated with EdU for the last 
48 h. Nestin protein and EdU incorporation were visualized by immunocytochemistry. 
Positive cells were counted by an automated screening microscope (1000 nuclei/condition). 
(D): The mAGES were exposed to increasing concentrations of U0126 in medium containing 
10 ng/ml BMP4 for 8 days. Resazurin reduction was measured and normalized to control 
without U0126 as a measure of viability. 
Supplemental figure Fig. S6: EGF signaling is not involved in mAGES de-differentiation.  
 (A): The mAGES were exposed to increasing concentrations of the EGF receptor inhibitor 
gefitinib (Gef) in medium containing 10 ng/ml BMP4 for 8 days. Resazurin reduction was 
measured and normalized to control without Gef as a measure of viability.  (B):  The mAGES 
(ctrl, no factors) were exposed to 20 ng/ml FGF2 plus increasing concentrations of gefitinib 
for 8 days. Resazurin reduction was used as surrogate measure of cell number. The data 
indicate the percentage of increased resazurin fluorescence signal (proportional to cell 
number) relative to ctrl conditions.  (C): The mAGES were exposed to gefitinib (1 µM) in 
medium containing either no factors or 20 ng/ml FGF2 for 8 days, and incubated with EdU 
for the last 48 h. EdU incorporation, nestin or GFAP protein (green) were visualized by 
immunocytochemistry. Nuclei were stained with H-33342 (blue). Gefitinib (1 µM) revealed 
no influence on mAGES exposed to FGF2. (D) Densitometric quantification of the ratio 
between phosphorylated and un-phosphorylated proteins from three experiments as in Fig. 3F. 
***, p <0.0001; **, p <0.001 (Tukey’s posttest). 
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Supplemental figure Fig. S7: Display of the mean expression for the astrocytes or NSC 
marker genes depicted in the heatmap of Fig. 5C.  
Gene expression analysis (Affymetrix Mouse Genome 430 2.0 arrays) of the previously 
identified astrocyte (blue) and NSC (red) marker genes [51] in NSC, mAGES, and NSC2 
from 4 independent differentiations. The logarithmized (to the base of 2) mean expression 
values, standard deviation, and fold changes relative to NSC are listed.  
Supplemental figure Fig. S8: NSC2 resemble NSC in gene expression of NSC-selectivity 
markers identified by Beckervordersandforth et al. 2010 [88].  
Heatmap of gene expression values for the NSC selectivity markers identified by 
Beckervordersandforth et al. 2010 (listed vertically) [88]. The normalized (z-scores) 
expression data are plotted for four NSC, four mAGES, and three NSC2 samples (listed 
horizontally) for each of the marker genes. Blue colors represent low, red colors high 
expression, with z-scores from 2 to -6. Full gene names and corresponding absolute 
expression values are listed in Supporting_Information_ Fig. S9. Red highlighted genes were 
selective for NSC, while yellow highlighted genes showed high variation between mAGES 
samples. 
Supplemental figure Fig. S9: Display of the mean expression values for the NSC-selectivity 
marker genes depicted in the heatmap of Supporting_Information_Fig. S8. 
Gene expression analysis (Affymetrix Mouse Genome 430 2.0 arrays) of the previously 
identified NSC-selectivity marker genes [88] in NSC, mAGES, and NSC2 from 4 
independent differentiations. The logarithmized (to the base of 2) mean expression values, 
standard deviation, and fold changes relative to NSC are listed. Red highlighted genes were 
selective for NSC, while yellow highlighted genes showed high variation between mAGES 
samples.  
Kleiderman et al.: astrocyte reactivation by FGF2 
 
37 (of 40) 
Supplemental figure Fig. S10: Detailed information on NSC2 generation from differentiated 
astrocytes.  
(A): Cultures of mAGES (ctrl, no factors) were exposed to 20 ng/ml FGF2 for up to 8 days 
without medium exchange, and LDH release was measured to determine cell death during de-
differentiation. (B): The mAGES were labeled with carboxyfluorescein (CFSE) and exposed 
to 20 ng/ml FGF2 for 10 days (red). As control, mAGES were cultured in medium without 
additional factors (ctrl, green). CFSE intensity of 20,000 viable cells per condition was 
measured with a high throughput imaging device. A histogram of CFSE intensity (note 
logarithmic axis scaling) against cell count was produced. A threshold comprising 95% of the 
cells in control cultures was used to distinguish between dividing and non-dividing cells. The 
percentage of non-dividing cells in FGF2-exposed cultures is indicated in red. Further 
thresholds produced by dividing the upper threshold by 2 (CFSE label is halved during cell 
division) were used to determine the amount of cells, which divided once (1x), twice (2x), or 
three-times (3x). To normalize the data and to determine the percentage of cells, which 
divided or not with regard to the starting population, the amount of cells, which divided once, 
was divided by 2, the amount of cells, which divided twice, was divided by 4, and so forth. 
The percentage of non-dividing cells after normalization is given in blue (C,D): The mAGES 
were transfected with DsRed and exposed to 20 ng/ml FGF2 for 10 days. Fluorescent pictures 
of the red channel were taken with a live imaging microscope every 5 h. 84 single cells have 
been tracked using Timm’s Tracking Tool (TTT) and lineage trees of single cells have been 
generated. (C): The percentage of cells, which did not divide or which divided once, twice or 
three-times, has been calculated. Representative lineage trees for each group were chosen. 
(D): The day of the first cell division of the single cells has been determined and 4 groups 
have been chosen giving the percentage of cells in each group. Representative lineage trees 
for each group were chosen.  
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Supplemental figure Fig. S11: Time-lapse microscopy of FGF2-induced de-differentiation of 
mAGES.  
(A,C): The mAGES were exposed to 20 ng/ml FGF2 and phase contrast pictures were taken 
with a live imaging microscope every 15 min from day 3-10. Videos of mAGES exposed to 
FGF2 (video 2) as well as of control cultures (no factors, video 3) are attached in the 
Supplemental figure. A picture sequence of dividing cells from the black edging in (A) is 
shown in (C). (B,D): The mAGES were transfected with DsRed and exposed to 20 ng/ml 
FGF2. Fluorescent pictures of the red channel were taken with a live imaging microscope 
every 5 h until day 10 (video 1). A picture sequence of dividing cells from the black edging 
(B) is shown in (D).  
Supplemental figure Fig. S12: Block of the generation of NSC2 from mAGES by inflammatory 
cytokines.  
(A): The mAGES (ctrl, no factors) were exposed to 20 ng/ml FGF2 plus various combinations 
of inflammatory cytokines (10 ng/ml TNFα, 10 ng/ml IL1β, 20 ng/ml IFNγ) or a complete 
cytokine mix (CCM) containing all three cytokines for 8 days. EdU incorporation and 
nestin/GFAP protein were visualized by immunocytochemistry. (B): The mAGES (ctrl, no 
factors) were treated as in (A), and nestin was visualized by immunocytochemistry. Positive 
cells were counted by an automated screening microscope (1000 nuclei/condition). ***, p 
<.0001; **, p <.001; *, p <.01; ns not significant (versus FGF2). (C): The mAGES (ctrl, no 
factors) were treated as in (A), and GFAP was visualized by immunocytochemistry. Positive 
cells were counted by an automated screening microscope (1000 nuclei/condition). ***, p 
<.0001; **, p <.001; ns not significant (versus FGF2). 
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Supplemental figure Fig. S13: Ruxolitinib prevents IFNγ-induced inhibition of NSC2 
generation.  
(A): The mAGES (ctrl, no factors) were exposed to 20 ng/ml FGF2 plus IFNγ and increasing 
concentrations of ruxolitinib (Rux) for 8 days. Resazurin reduction was used as surrogate 
measure of cell number. The data indicate the percentage of increased resazurin fluorescence 
signal (proportional to cell number) relative to ctrl conditions. (B): The experiment was 
performed as in (A), with complete cytokine mix (CCM) instead of IFNγ. (C): Cultures of 
mAGES were pre-incubated for 24 h with 20 ng/ml INFγ and/or for 30 min with the 
JAK/STAT inhibitor ruxolitinib, and exposed to 20 ng/ml FGF2 for 20 min. Cell lysates were 
analyzed by Western blot for the phosphorylated forms STAT1 (pSTAT1, phosphorylation at 
either serine residue 727 or tyrosine residue 701). Actin was used as loading control. (D): 
Cultures of mAGES were pre-incubated for 30 min with the JAK/STAT inhibitor ruxolitinib 
(Rux) and/or 20 ng/ml INFγ, and exposed to 20 ng/ml FGF2 for 20 min. Cell lysates were 
analyzed by Western blot for the phosphorylated forms of ERK (pERK) and STAT1 
(pSTAT1, phosphorylation at serine residue 727). Actin was used as loading control.  
Supplemental Video 1: Time-lapse imaging of DsRed-transfected mAGES exposed to FGF2. 
NSC were seeded at high density (50,000 cells/cm2) and differentiated into mAGES with 20 
ng/ml BMP4 for 3 days. Then, mAGES were transfected with DsRed, washed, and exposed to 
20 ng/ml FGF2. Fluorescent pictures of the red channel were taken with a live imaging 
microscope every 5 h until day 10. The movie shows 2 frames per second. 
Supplemental Video 2: Time-lapse imaging of mAGES exposed to FGF2 in low-density 
culture. 
NSC were seeded at low density (25,000 cells/cm2) and differentiated into mAGES with 20 
ng/ml BMP4 for 3 days. Then, cells were washed and mAGES were exposed to 20 ng/ml 
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FGF2. Phase contrast pictures were taken with a live imaging microscope every 15 min from 
day 3-10. The movie shows 15 frames per second. 
Supplemental Video 3: Time-lapse imaging of mAGES in low-density culture (no factors). 
NSC were seeded at low density (25,000 cells/cm2) and differentiated into mAGES with 20 
ng/ml BMP4 for 3 days. Then, cells were washed and mAGES were maintained in N2B27-
medium without any additional factors to exclude the induction of cell division by the 
withdrawal of BMP4. Phase contrast pictures were taken with a live imaging microscope 
every 15 min from day 3-10. The movie shows 15 frames per second. 
 
